Status:
NOT_YET_RECRUITING
Analytical Treatment Interruption in a Patient With HIV Post Allogeneic Stem Cell Transplantation From a CCR5 delta32 Homozygous Donor
Lead Sponsor:
University of Kansas Medical Center
Collaborating Sponsors:
National Institutes of Health (NIH)
Conditions:
HIV-1-infection
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Patients who have Human Immunodeficiency Virus-1 (HIV-1) infection, who also had a stem cell transplant may have achieved cure of their HIV infection. Once the patients blood shows no detectable level...
Detailed Description
On week -1, a HIV VL and CD4 count will be drawn. If VL remains undetectable, at study week 0, and no other exclusion criteria noted, subject will discontinue ART and enter ATI phase of the study. HIV...
Eligibility Criteria
Inclusion
- Positive HIV testing
- Has undergone a stem cell transplant
Exclusion
- under 18 years of age
- unwilling to comply with protocol
Key Trial Info
Start Date :
September 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2034
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT06582797
Start Date
September 1 2024
End Date
September 1 2034
Last Update
September 3 2024
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.